MOREPENLAB Stock Overview
Develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), formulations, and home health products in India, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Morepen Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹78.97 |
| 52 Week High | ₹100.90 |
| 52 Week Low | ₹38.55 |
| Beta | 1.56 |
| 1 Month Change | -8.55% |
| 3 Month Change | -6.44% |
| 1 Year Change | 57.78% |
| 3 Year Change | 39.28% |
| 5 Year Change | 409.48% |
| Change since IPO | -48.81% |
Recent News & Updates
Recent updates
There's Reason For Concern Over Morepen Laboratories Limited's (NSE:MOREPENLAB) Massive 30% Price Jump
Aug 20
Impressive Earnings May Not Tell The Whole Story For Morepen Laboratories (NSE:MOREPENLAB)
Aug 09Improved Earnings Required Before Morepen Laboratories Limited (NSE:MOREPENLAB) Stock's 29% Jump Looks Justified
Jul 05Does Morepen Laboratories (NSE:MOREPENLAB) Have A Healthy Balance Sheet?
Jun 13Morepen Laboratories Limited's (NSE:MOREPENLAB) Popularity With Investors Is Under Threat From Overpricing
Apr 23Morepen Laboratories (NSE:MOREPENLAB) Seems To Use Debt Quite Sensibly
Nov 23Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 22Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
Aug 10Increases to CEO Compensation Might Be Put On Hold For Now at Morepen Laboratories Limited (NSE:MOREPENLAB)
Sep 21Should You Be Adding Morepen Laboratories (NSE:MOREPENLAB) To Your Watchlist Today?
Apr 05Do Morepen Laboratories's (NSE:MOREPENLAB) Earnings Warrant Your Attention?
Sep 14Is Morepen Laboratories (NSE:MOREPENLAB) Using Too Much Debt?
May 21Does Morepen Laboratories (NSE:MOREPENLAB) Deserve A Spot On Your Watchlist?
Mar 12Our View On Morepen Laboratories' (NSE:MOREPENLAB) CEO Pay
Feb 22Is Morepen Laboratories Limited's (NSE:MOREPENLAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 07Morepen Laboratories (NSE:MOREPENLAB) Shareholders Have Enjoyed A 91% Share Price Gain
Jan 21Morepen Laboratories (NSE:MOREPENLAB) Has A Pretty Healthy Balance Sheet
Jan 03
Is There More To The Story Than Morepen Laboratories's (NSE:MOREPENLAB) Earnings Growth?
Dec 16Shareholder Returns
| MOREPENLAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 2.7% | 3.0% | 1.8% |
| 1Y | 57.8% | 36.5% | 18.0% |
Return vs Industry: MOREPENLAB exceeded the Indian Pharmaceuticals industry which returned 36.5% over the past year.
Return vs Market: MOREPENLAB exceeded the Indian Market which returned 18% over the past year.
Price Volatility
| MOREPENLAB volatility | |
|---|---|
| MOREPENLAB Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: MOREPENLAB has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: MOREPENLAB's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 2,152 | Sushil Suri | www.morepen.com |
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), formulations, and home health products in India, the United States, and internationally. The company offers APIs for anti-histaminic, anti-asthmatic, anti-lipemic, anti-hypertensive, anti-diabetic, anti-coagulant, anti-gout, anti-depressant, and anti-malarial drugs; and home diagnostic products, such as air purifiers, sphygmomanometer, blood glucose test strips, blood pressure monitors, breathe free vaporizers, stethoscopes, digital thermometers, blood glucose monitors, nebulizers, heat belts, and pulse oximeters. It also provides fever X for fever; Pain X for pain; Fiber-X, a sat isabgol; Acidity X for acidity; Burnol, first degree/minor burns cream; and formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, anti-allergic, and central nervous system, as well as cardiology, diabetology, and nutraceuticals.
Morepen Laboratories Limited Fundamentals Summary
| MOREPENLAB fundamental statistics | |
|---|---|
| Market cap | ₹43.25b |
| Earnings (TTM) | ₹1.31b |
| Revenue (TTM) | ₹17.75b |
33.0x
P/E Ratio2.4x
P/S RatioIs MOREPENLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MOREPENLAB income statement (TTM) | |
|---|---|
| Revenue | ₹17.75b |
| Cost of Revenue | ₹11.10b |
| Gross Profit | ₹6.65b |
| Other Expenses | ₹5.34b |
| Earnings | ₹1.31b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.40 |
| Gross Margin | 37.48% |
| Net Profit Margin | 7.40% |
| Debt/Equity Ratio | 3.0% |
How did MOREPENLAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 13:15 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Morepen Laboratories Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Vijay Madunala | FirstCall Research |